Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
san diego blog main
4
×
clinical trials
fda
national top stories
new york blog main
san diego top stories
akcea therapeutics
alnylam pharmaceuticals
biotech
dyne therapeutics
hereditary transthyretin amyloidosis
inotersen
myotonic dystrophy type 1
new york top stories
onpattro
patisiran
pfizer
rare disease drugs
san francisco blog main
tafamidis
andrew fire
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
bluebird bio
craig mello
drugs
duchenne muscular dystrophy
european medicines agency
facioscapulohumeral muscular dystrophy
gene therapy
harvard pilgrim health care
institute for clinical and economic review
What
drug
4
×
alnylam
dyne
fda
genetic
ipo
medicine
medicines
muscle
rare
rnai
therapeutics
afternoon
ago
alnylam’s
approved
approves
biotechs
brings
cells
company
considering
data
developing
diseases
disorders
dyne’s
early
ema
employ
europe
expected
experimental
eyes
follows
gene
gets
harmful
having
history
Language
unset
Current search:
boston
×
drug
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
